To interrupt the spread of the disease, a test needs to be sensitive enough to identify people with low-level infections.
The findings could enable doctors to detect early on if a treatment is working and switch to alternatives such as abiraterone or cabazitaxel if it is not.
A prostate cancer urine test can identify men at intermediate risk of aggressive disease, who can safely avoid immediate treatment.
Researchers investigated the efficacy of salivary HPV detection as a biomarker of HPV-driven head and neck cancers.
Liver damage caused by a life-threatening genetic blood disorder, known as hereditary haemochromatosis, can be detected with a simple blood test or scan.
A new test could help reduce the high mortality rate from ovarian cancer by dramatically improving the accuracy of early detection.
Vets have developed a diagnostic point-of-care kit that is claimed to detect the deadly Hendra virus in horses faster than ever — in under an hour, rather than days.
Blood-based measurement of glial fibrillary acidic protein (GFAP) can distinguish patients with frontotemporal dementia from those with primary psychiatric disorders or healthy individuals.
The kit could facilitate the diagnosis of malaria in the field, as it is anticipated to be lightweight, easy to use and able to detect the disease in its early stages.
Many of the cancers that the test is capable of detecting do not have screening tests available, such as liver, pancreatic and oesophageal cancers.
The odour-based test sniffs out vapours emanating from blood samples and is able to distinguish between benign, pancreatic and ovarian cancer cells.
Researchers have developed a rapid and sensitive testing method for COVID-19 biomarkers, claimed to provide results in just one second.
An experimental new urine test for prostate cancer has the potential to revolutionise how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy.
Researchers have developed a gene panel test that allows for highly accurate diagnosis of the most common types of liposarcoma.
Queensland-based company Ellume has announced a US$231.8 million (AU$302.7 million) agreement to accelerate domestic US production of its COVID-19 home tests.